Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept + Paclitaxel in Advanced Gastric/GEJ Cancer
NCT04555304Phase 2Unknown
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- Sep 2020
- Primary completion
- Jan 2022
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 2 trial of conbercept in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd.. Status: unknown.
02
Drugs
conbercept
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04555304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04555304.